Market News AIOpen the app

SELLAS Life Sciences Group, Inc.: Regulation FD Disclosure (SLS)

TrialRead the original at SEC EDGAR
Good for SLS

SELLAS reported longer survival and a lower risk of death with GPS than with the comparison treatment. This supports the company's prospects, though FDA talks and an approval application are still ahead.

SLS · SELLAS Life Sciences Group, Inc.

AI read · Good for SLS

The AI's read

The longer survival and lower death risk support GPS as a possible treatment for this group. SELLAS still plans FDA talks and an approval application, so GPS is not yet approved.

Get alerts for SLS

Follow SELLAS Life Sciences Group, Inc. (SLS) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for SLS
Free on the App Store and Google Play, or on the web.